PURPOSE: TACE induces variable systemic effects by producing factors that promote inflammation, oncogenesis, and angiogenesis. Here we compare concentrations of microRNAs (miR-21, miR-210 and miR-34a) and vascular endothelial growth factor (VEGF) in hepatocellular carcinoma (HCC) patients undergoing TACE with degradable (DSM) and nondegradable (DEB) particles and potential use of these biomarker changes for prediction of patient outcomes. MATERIALS AND METHODS: Overall, 52 patients with HCC treated with DSM TACE (24 patients) and DEB TACE (28 patients) were included in this prospective study. Concentrations of studied biomarkers were measured from blood plasma preprocedurally, immediately (< 90 min) postprocedurally, and 24-h after TACE. Levels were compared between DSM and DEB TACE and correlated with treatment response six and 12 months after the first TACE. RESULTS: Both DSM and DEB TACE elevated plasma levels of miR-21, miR-34a, and miR-210 at 24 h post-procedure compared to baseline levels (FC 1.25-4.0). MiR-34a elevation immediately after TACE was significantly associated with nonprogressive disease compared to those with progressive disease at both six months (FCa: p = 0.014) and 12 months (FCa: p = 0.029) post-TACE. No significant biomarker changes were found between the embolization particle groups. However, VEGF levels showed a decrease only in the DSM TACE group (FC24: p = < 0.001). CONCLUSION: Embolization particle type did not significantly impact miRNA or VEGF changes post-TACE. However, miR-34a elevation immediately after the procedure predicts better patient outcome and may prove useful as a biomarkers for the monitoring of clinical outcomes. LEVEL OF EVIDENCE: Level 3 Prospective cohort study.

Central European Institute of Technology Kamenice 753 5 625 00 Brno Czechia

CERIT SC Centre Institute of Computer Science Masaryk University Šumavská 416 15 602 00 Brno Czechia

Department of Applied Mathematics Faculty of Electrical Engineering and Computer Science VSB Technical University of Ostrava 17 Listopadu 2172 15 708 00 Ostrava Czechia

Department of Radiology and Nuclear Medicine University Hospital Brno and Masaryk University Brno Jihlavská 340 20 625 00 Brno Czechia

Hadassah Hebrew University Medical Center Ein Karem Jerusalem Israel

Masaryk Memorial Cancer Institute Žlutý Kopec 543 7 602 00 Brno Czechia

Zobrazit více v PubMed

Yang ZF, Poon RTP. Vascular changes in hepatocellular carcinoma. Anat Rec (Hoboken). 2008;291:721–34. https://doi.org/10.1002/ar.20668 . PubMed DOI

Kulshreshtha R, Ferracin M, Wojcik SE, et al. A microRNA signature of hypoxia. Mol Cell Biol. 2007;27:1859–67. https://doi.org/10.1128/MCB.01395-06 . PubMed DOI PMC

Chan YC, Banerjee J, Choi SY, Sen CK. miR-210: the master hypoxamir. Microcirculation. 2012;19:215–23. https://doi.org/10.1111/j.1549-8719.2011.00154.x . PubMed DOI PMC

Fasanaro P, D’Alessandra Y, Di Stefano V, et al. MicroRNA-210 modulates endothelial cell response to hypoxia and inhibits the receptor tyrosine kinase ligand Ephrin-A3. J Biol Chem. 2008;283:15878–83. https://doi.org/10.1074/jbc.M800731200 . PubMed DOI PMC

Camps C, Buffa FM, Colella S, et al. hsa-miR-210 Is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin Cancer Res. 2008;14:1340–8. https://doi.org/10.1158/1078-0432.CCR-07-1755 . PubMed DOI

Potente M, Gerhardt H, Carmeliet P. Basic and therapeutic aspects of angiogenesis. Cell. 2011;146:873–87. https://doi.org/10.1016/j.cell.2011.08.039 . PubMed DOI

Bozzato AM, Martingano P, PozziMucelli RA, et al. MicroRNAs related to TACE treatment response: a review of the literature from a radiological point of view. Diagnostics (Basel). 2022;12:374. https://doi.org/10.3390/diagnostics12020374 . PubMed DOI

Kaller M, Liffers S-T, Oeljeklaus S, et al. Genome-wide characterization of miR-34a induced changes in protein and mRNA expression by a combined pulsed SILAC and microarray analysis. Mol Cell Proteomics. 2011;10(M111):010462. https://doi.org/10.1074/mcp.M111.010462 . DOI

Farooqi AA, Tabassum S, Ahmad A. MicroRNA-34a: a versatile regulator of myriads of targets in different cancers. Int J Mol Sci. 2017;18:2089. https://doi.org/10.3390/ijms18102089 . PubMed DOI PMC

Shi K, Sun H, Zhang H, et al. miR-34a-5p aggravates hypoxia-induced apoptosis by targeting ZEB1 in cardiomyocytes. Biol Chem. 2019;400:227–36. https://doi.org/10.1515/hsz-2018-0195 . PubMed DOI

Liu J, Zhu H, Yang X, et al. MicroRNA-21 is a novel promising target in cancer radiation therapy. Tumor Biol. 2014;35:3975–9. https://doi.org/10.1007/s13277-014-1623-8 . DOI

Lendvai G, Szekerczés T, Gyöngyösi B, et al. MicroRNA expression in focal nodular hyperplasia in comparison with cirrhosis and hepatocellular carcinoma. Pathol Oncol Res. 2019;25:1103–9. https://doi.org/10.1007/s12253-018-0528-z . PubMed DOI

Wiggermann P, Wohlgemuth WA, Heibl M, et al. Dynamic evaluation and quantification of microvascularization during degradable starch microspheres transarterial chemoembolisation (DSM-TACE) of HCC lesions using contrast enhanced ultrasound (CEUS): a feasibility study. Clin Hemorheol Microcirc. 2013;53:337–48. https://doi.org/10.3233/CH-2012-1555 . PubMed DOI

Ebert M, Ebert J, Berger G. Intravital microscopic research of microembolization with degradable starch microspheres. J Drug Deliv. 2013;2013:242060. https://doi.org/10.1155/2013/242060 . PubMed DOI PMC

Andrasina T, Juracek J, Zavadil J, et al. Thermal ablation and transarterial chemoembolization are characterized by changing dynamics of circulating MicroRNAs. J Vasc Interv Radiol. 2021;32:403–11. https://doi.org/10.1016/j.jvir.2020.10.024 . PubMed DOI

Zavadil J, Juráček J, Čechová B, et al. Dynamic changes in circulating MicroRNA levels in liver cancer patients undergoing thermal ablation and transarterial chemoembolization. Klin Onkol. 2019;32:164–6. PubMed

Schicho A, Hellerbrand C, Krüger K, Beyer LP, Wohlgemuth W, Niessen C, Hohenstein E, Stroszczynski C, Pereira PL, Wiggermann P. Impact of different embolic agents for transarterial chemoembolization (TACE) procedures on systemic vascular endothelial growth factor (VEGF) levels. J Clin Transl Hepatol. 2016;4(4):288. PubMed DOI PMC

Stechele M, Link H, Hirner-Eppeneder H, et al. Circulating miR-21 as a prognostic biomarker in HCC treated by CT-guided high-dose rate brachytherapy. Radiat Oncol. 2023;18:125. https://doi.org/10.1186/s13014-023-02316-2 . PubMed DOI PMC

Zhan M, Li Y, Hu B, et al. Serum microRNA-210 as a predictive biomarker for treatment response and prognosis in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. J Vasc Interv Radiol. 2014;25:1279-1287.e1. https://doi.org/10.1016/j.jvir.2014.04.013 . PubMed DOI

Jia Z, Jiang G, Feng Y. Serum HIF-1alpha and VEGF levels pre- and post-TACE in patients with primary liver cancer. Chin Med Sci J. 2011;26:158–62. https://doi.org/10.1016/s1001-9294(11)60041-2 . PubMed DOI

Shim JH, Park J-W, Kim JH, et al. Association between increment of serum VEGF level and prognosis after transcatheter arterial chemoembolization in hepatocellular carcinoma patients. Cancer Sci. 2008;99:2037–44. https://doi.org/10.1111/j.1349-7006.2008.00909.x . PubMed DOI PMC

Chao Y, Wu C-Y, Kuo C-Y, et al. Cytokines are associated with postembolization fever and survival in hepatocellular carcinoma patients receiving transcatheter arterial chemoembolization. Hepatol Int. 2013;7:883–92. https://doi.org/10.1007/s12072-012-9409-9 . PubMed DOI

Poon RT-P, Lau C, Yu W-C, et al. High serum levels of vascular endothelial growth factor predict poor response to transarterial chemoembolization in hepatocellular carcinoma: a prospective study. Oncol Rep. 2004;11:1077–84. PubMed

Hsieh M-Y, Lin Z-Y, Chuang W-L. Serial serum VEGF-A, angiopoietin-2, and endostatin measurements in cirrhotic patients with hepatocellular carcinoma treated by transcatheter arterial chemoembolization. Kaohsiung J Med Sci. 2011;27:314–22. https://doi.org/10.1016/j.kjms.2011.03.008 . PubMed DOI

Pelizzaro F, Cardin R, Sartori A, et al. Circulating MicroRNA-21 and MicroRNA-122 as prognostic biomarkers in hepatocellular carcinoma patients treated with transarterial chemoembolization. Biomedicines. 2021;9:890. https://doi.org/10.3390/biomedicines9080890 . PubMed DOI PMC

Cui X, Wu Y, Wang Z, et al. MicroRNA-34a expression is predictive of recurrence after radiofrequency ablation in early hepatocellular carcinoma. Tumour Biol. 2015;36:3887–93. https://doi.org/10.1007/s13277-014-3031-5 . PubMed DOI

Canale M, Foschi FG, Andreone P, et al. Role of circulating microRNAs to predict hepatocellular carcinoma recurrence in patients treated with radiofrequency ablation or surgery. HPB. 2022;24:244–54. https://doi.org/10.1016/j.hpb.2021.06.421 . PubMed DOI

Chen S, Mao Y, Chen W, et al. Serum exosomal miR-34a as a potential biomarker for the diagnosis and prognostic of hepatocellular carcinoma. J Cancer. 2022;13:1410–7. https://doi.org/10.7150/jca.57205 . PubMed DOI PMC

Lacombe J, Zenhausern F. Emergence of miR-34a in radiation therapy. Crit Rev Oncol Hematol. 2017;109:69–78. https://doi.org/10.1016/j.critrevonc.2016.11.017 . PubMed DOI

Oda T, Tsuda H, Scarpa A, et al. p53 gene mutation spectrum in hepatocellular carcinoma1. Can Res. 1992;52:6358–64.

Bahrami A, Aledavood A, Anvari K, et al. The prognostic and therapeutic application of microRNAs in breast cancer: Tissue and circulating microRNAs. J Cell Physiol. 2018;233:774–86. https://doi.org/10.1002/jcp.25813 . PubMed DOI

Bertoli G, Cava C, Castiglioni I. The potential of miRNAs for diagnosis, treatment and monitoring of breast cancer. Scand J Clin Lab Invest. 2016;76:S34–9. https://doi.org/10.1080/00365513.2016.1208444 . DOI

Brenner C, Galluzzi L, Kepp O, Kroemer G. Decoding cell death signals in liver inflammation. J Hepatol. 2013;59:583–94. https://doi.org/10.1016/j.jhep.2013.03.033 . PubMed DOI

Hendgen-Cotta UB, Luedike P, Totzeck M, et al. Dietary nitrate supplementation improves revascularization in chronic ischemia. Circulation. 2012;126:1983–92. https://doi.org/10.1161/CIRCULATIONAHA.112.112912 . PubMed DOI

Totzeck M, Schicho A, Stock P, et al. Nitrite circumvents canonical cGMP signaling to enhance proliferation of myocyte precursor cells. Mol Cell Biochem. 2015;401:175–83. https://doi.org/10.1007/s11010-014-2305-y . PubMed DOI

Kohli V, Selzner M, Madden JF, et al. Endothelial cell and hepatocyte deaths occur by apoptosis after ischemie-injury in the rat liver. Transplantation. 1999;67:1099. PubMed DOI

Lee K-H, Liapi E, Vossen JA, et al. Distribution of Iron oxide–containing embosphere particles after transcatheter arterial embolization in an animal model of liver cancer: evaluation with MR imaging and implication for therapy. J Vasc Interv Radiol. 2008;19:1490–6. https://doi.org/10.1016/j.jvir.2008.06.008 . PubMed DOI PMC

Li X, Feng G-S, Zheng C-S, et al. Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level. World J Gastroenterol. 2004;10:2878–82. https://doi.org/10.3748/wjg.v10.i19.2878 . PubMed DOI PMC

Ranieri G, Ammendola M, Marech I, et al. Vascular endothelial growth factor and tryptase changes after chemoembolization in hepatocarcinoma patients. World J Gastroenterol. 2015;21:6018–25. https://doi.org/10.3748/wjg.v21.i19.6018 . PubMed DOI PMC

Matsui D, Nagai H, Mukozu T, et al. VEGF in patients with advanced hepatocellular carcinoma receiving intra-arterial chemotherapy. Anticancer Res. 2015;35:2205–10. PubMed

Wang J, Yu J-P, Ni X-C, et al. Pathological response and serum VEGF changes during chemoradiotherapy for esophageal carcinoma. Medicine (Baltimore). 2019;98:e15627. https://doi.org/10.1097/MD.0000000000015627 . PubMed DOI

Liu K, Min XL, Peng J, Yang K, Yang L, Zhang XM. The changes of HIF-1α and VEGF expression after TACE in patients with hepatocellular carcinoma. J Clin Med Res. 2016;8(4):297. PubMed DOI PMC

Lee YK, Kim SU, Kim DY, et al. Prognostic value of α-fetoprotein and des-γ-carboxy prothrombin responses in patients with hepatocellular carcinoma treated with transarterial chemoembolization. BMC Cancer. 2013;13:5. https://doi.org/10.1186/1471-2407-13-5 . PubMed DOI PMC